What does this Instagram post claim?
Jarosław Sroka tells his 24,300 viewers that BPC-157 is a "Body Protecting Compound" peptide found naturally in stomach juice that's gaining recognition in medical and sports communities for healing injuries. He claims it speeds recovery from tendon, muscle, and bone damage while promoting angiogenesis (new blood vessel formation).
The post positions BPC-157 as a proven therapeutic compound with established regenerative properties. Sroka suggests it's becoming accepted in legitimate medical circles, not just fringe wellness communities.
Is BPC-157 actually found in human stomach juice?
This claim is accurate but incomplete. BPC-157 is derived from a larger protein called BPC (Body Protection Compound) that exists in human gastric juice, as shown in early research by Sikiric et al. (Digestive Diseases and Sciences, 1993). However, the BPC-157 peptide used in research and supplements is a synthetic 15-amino acid fragment, not the natural compound itself.
The synthetic version doesn't occur naturally in your stomach. It's a laboratory-created sequence designed to mimic what researchers thought were the active parts of the natural protein.
This distinction matters because natural occurrence doesn't automatically make the synthetic version safe or effective at the doses people actually take.
Does the science support BPC-157 for healing injuries?
The research is almost entirely limited to animal studies, and that's a major problem for Sroka's claims about medical acceptance. Most published research comes from one Croatian research group led by Sikiric, with studies in rats and mice showing accelerated healing of various tissues.
For example, Kang et al. (Journal of Applied Physiology, 2018) found BPC-157 improved Achilles tendon healing in rats. Chang et al. (Molecules, 2014) reported faster muscle healing, also in rodents.
But here's what Sroka doesn't mention: there are virtually no human clinical trials. The FDA hasn't approved BPC-157 for any medical use, and it's actually prohibited in dietary supplements. The "medical recognition" he claims is mostly happening in anti-aging clinics and online forums, not mainstream medicine.
What about the angiogenesis claim?
Sroka's angiogenesis claim has some animal study support. Krivic et al. (European Journal of Pharmacology, 2006) showed BPC-157 promoted blood vessel formation in rat models. Huang et al. (Regulatory Peptides, 2015) found similar effects in wound healing studies.
But promoting angiogenesis isn't automatically good. Cancer tumors also rely on angiogenesis to grow and spread. Without human safety studies, we don't know if BPC-157's blood vessel effects could be problematic in certain people.
The mechanism isn't well understood either. Researchers have proposed it might work through growth factor pathways, but the exact targets remain unclear after decades of study.
What should you actually know about BPC-157?
BPC-157 remains an experimental compound with promising animal data but virtually no human evidence. The peptide community's enthusiasm has far outpaced the actual science, and Sroka's post reflects that gap.
If you're considering BPC-157, know that you're essentially participating in an uncontrolled experiment. Quality control is inconsistent since it's not regulated as a drug. Prices range from $50-200+ for a vial, with no standardized dosing protocols.
Most concerning is how the lack of human trials means we don't understand long-term effects, optimal dosing, or potential interactions with other medications. The animal studies use various doses and delivery methods, making it impossible to extrapolate safe human protocols.